Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.

@article{Visser2010EffectOA,
  title={Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.},
  author={Maartje Visser and Fatima Akdim and Diane L. Tribble and Aart J. Nederveen and T. Jesse Kwoh and John J. P. Kastelein and Mieke D. Trip and Erik S. G. Stroes},
  journal={Journal of lipid research},
  year={2010},
  volume={51 5},
  pages={1057-62}
}
To investigate the impact of mipomersen, an apolipoprotein B-100 (apoB) synthesis inhibitor, on intra-hepatic triglyceride content (IHTG content), we conducted a randomized, double-blind, placebo-controlled study in 21 patients with familial hypercholesterolemia (FH). Subjects received a weekly subcutaneous dose of 200 mg mipomersen or placebo for 13 weeks while continuing conventional lipid lowering therapy. The primary endpoint was change in IHTG content from week 0 to week 15 as measured by… CONTINUE READING